IL2 and graft versus host disease: Unlike the syngeneic setting, CsA and IL-2 does not suppress allogeneic immune responses, indicating that IL-2 treatment against acute GVHD would not be recommended in the clinical setting because almost all recipients are treated with a calcineurin inhibitor for GVHD prophylaxis.